200 related articles for article (PubMed ID: 32691270)
1. The Importance of Countering Biosimilar Disparagement and Misinformation.
Cohen HP; McCabe D
BioDrugs; 2020 Aug; 34(4):407-414. PubMed ID: 32691270
[TBL] [Abstract][Full Text] [Related]
2. European Stakeholder Learnings Regarding Biosimilars: Part I-Improving Biosimilar Understanding and Adoption.
Barbier L; Simoens S; Vulto AG; Huys I
BioDrugs; 2020 Dec; 34(6):783-796. PubMed ID: 33141421
[TBL] [Abstract][Full Text] [Related]
3. European Stakeholder Learnings Regarding Biosimilars: Part II-Improving Biosimilar Use in Clinical Practice.
Barbier L; Simoens S; Vulto AG; Huys I
BioDrugs; 2020 Dec; 34(6):797-808. PubMed ID: 33063267
[TBL] [Abstract][Full Text] [Related]
4. Assessing awareness and attitudes of healthcare professionals on the use of biosimilar medicines: A survey of physicians and pharmacists in Ireland.
O'Callaghan J; Bermingham M; Leonard M; Hallinan F; Morris JM; Moore U; Griffin BT
Regul Toxicol Pharmacol; 2017 Aug; 88():252-261. PubMed ID: 28666961
[TBL] [Abstract][Full Text] [Related]
5. Biosimilars: Practical Considerations for Pharmacists.
Stevenson JG; Popovian R; Jacobs I; Hurst S; Shane LG
Ann Pharmacother; 2017 Jul; 51(7):590-602. PubMed ID: 28176529
[TBL] [Abstract][Full Text] [Related]
6. Knowledge and perception of biosimilars in ambulatory care: a survey among Belgian community pharmacists and physicians.
Barbier L; Vandenplas Y; Simoens S; Declerck P; Vulto AG; Huys I
J Pharm Policy Pract; 2021 Jun; 14(1):53. PubMed ID: 34158128
[TBL] [Abstract][Full Text] [Related]
7. Regulatory Information and Guidance on Biosimilars and Their Use Across Europe: A Call for Strengthened One Voice Messaging.
Barbier L; Mbuaki A; Simoens S; Declerck P; Vulto AG; Huys I
Front Med (Lausanne); 2022; 9():820755. PubMed ID: 35355594
[TBL] [Abstract][Full Text] [Related]
8. The growing role of biologics and biosimilars in the United States: Perspectives from the APhA Biologics and Biosimilars Stakeholder Conference.
Crespi-Lofton J; Skelton JB
J Am Pharm Assoc (2003); 2017; 57(5):e15-e27. PubMed ID: 28689708
[TBL] [Abstract][Full Text] [Related]
9. Pharmacists' Perspectives of Biosimilars: A Systematic Review.
Mohd Sani N; Aziz Z; Panickar R; Kamarulzaman A
BioDrugs; 2022 Jul; 36(4):489-508. PubMed ID: 35776294
[TBL] [Abstract][Full Text] [Related]
10. Differences in UK healthcare professionals' knowledge, attitude and practice towards infliximab and insulin glargine biosimilars.
Aladul MI; Fitzpatrick RW; Chapman SR
Int J Pharm Pract; 2019 Apr; 27(2):214-217. PubMed ID: 30160324
[TBL] [Abstract][Full Text] [Related]
11. Clinical and Regulatory Concerns of Biosimilars: A Review of Literature.
Halimi V; Daci A; Ancevska Netkovska K; Suturkova L; Babar ZU; Grozdanova A
Int J Environ Res Public Health; 2020 Aug; 17(16):. PubMed ID: 32796549
[TBL] [Abstract][Full Text] [Related]
12. Preparing for the market entry of adalimumab biosimilars in the US in 2023: A primer for specialty pharmacists.
Cisek S; Choi D; Stubbings J; Bhat S
Am J Health Syst Pharm; 2023 Sep; 80(18):1223-1233. PubMed ID: 37257054
[TBL] [Abstract][Full Text] [Related]
13. Perspectives of Hospital Pharmacists Towards Biosimilar Medicines: A Survey of Polish Pharmacy Practice in General Hospitals.
Pawłowska I; Pawłowski L; Krzyżaniak N; Kocić I
BioDrugs; 2019 Apr; 33(2):183-191. PubMed ID: 30830647
[TBL] [Abstract][Full Text] [Related]
14. Healthcare professionals' perceptions and perspectives on biosimilar medicines and the barriers and facilitators to their prescribing in UK: a qualitative study.
Aladul MI; Fitzpatrick RW; Chapman SR
BMJ Open; 2018 Nov; 8(11):e023603. PubMed ID: 30455389
[TBL] [Abstract][Full Text] [Related]
15. Perception of pharmacological equivalence of generics or biosimilars in healthcare professionals in Vienna.
Binder L; Zeitlinger M
Eur J Clin Pharmacol; 2024 Mar; 80(3):355-366. PubMed ID: 38133831
[TBL] [Abstract][Full Text] [Related]
16. Understanding US Physician and Pharmacist Attitudes Toward Biosimilar Products: A Qualitative Study.
Rupert DJ; Jordan AM; Ziemian MA; Brown RM; Fleming NS; Lefebvre RC
BioDrugs; 2022 Sep; 36(5):645-655. PubMed ID: 35962911
[TBL] [Abstract][Full Text] [Related]
17. Nurses' Knowledge and Attitudes towards Biosimilar Medicines as Part of Evidence-Based Nursing Practice-International Pilot Study within the Project Biosimilars Nurses Guide Version 2.0.
Friganović A; Mędrzycka-Dąbrowska W; Krupa S; Oomen B; Decock N; Stievano A
Int J Environ Res Public Health; 2022 Aug; 19(16):. PubMed ID: 36011946
[TBL] [Abstract][Full Text] [Related]
18. Moving forward: Implementing health psychology research to improve patient acceptance of biosimilars.
Gasteiger C; Petrie KJ
Res Social Adm Pharm; 2022 Oct; 18(10):3860-3863. PubMed ID: 35339394
[TBL] [Abstract][Full Text] [Related]
19. Knowledge, perceptions, attitude, barriers and facilitators of biosimilars use across specialty physicians and hospital pharmacists: A national survey.
Marín-Jiménez I; Carrascosa JM; Guigini MA; Monte-Boquet E
Farm Hosp; 2021 Jul; 45(5):240-246. PubMed ID: 34806583
[TBL] [Abstract][Full Text] [Related]
20. Knowledge and attitudes of German and Swiss community pharmacists towards biologicals and biosimilars - a prospective survey before and after the COVID-19 pandemic.
Messner K; Eickhoff C; Schulz M; Allemann SS; Arnet I
BMC Health Serv Res; 2023 Dec; 23(1):1432. PubMed ID: 38110932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
